BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market

  • BioMarin Pharmaceutical Inc BMRN reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million.
  • The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq.
  • Kuvan sales decreased 23% to $ 68.5 million, primarily due to generic competition.
  • Lower Naglazyme product revenues declined 31% to $83.1 million, primarily driven by the timing of orders from Latin America, the Middle East, and Europe.
  • Related: FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold.
  • Aldurazyme product revenues increased to $20.3 million due to the timing of product fulfillment to Sanofi SA SNY.
  • Palynziq sales increased 29% to $63.8 million primarily due to a combination of more patients in the U.S. achieving maintenance dosing and new patients initiating therapy.
  • Vimizim product revenues reached $156.3 million, +10% primarily driven by the timing of orders in the Middle East and Latin America.
  • BioMarin posted an EPS loss of $(0.32), compared to earnings of $0.12, in line with the consensus estimate.
  • The Company reported a wider operating loss of $(65.9) million than $(44.84) in Q4 FY20.
  • Guidance: BioMarin expects FY22 sales of $2.05 billion - $2.15 billion, versus the consensus of $2.14 billion.
  • It forecasts an adjusted income of $350 million - $390 million.
  • Price Action: BMRN shares closed at $82.52 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!